US Pharma MarketingSanofi abandons eczema drug approval efforts in another blow to OX40 class
Sanofi abandons eczema drug approval efforts in another blow to OX40 class is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Sanofi is ceasing development of amlitelimab due to concerns around the drug's differential value from other eczema treatment offerings.
Source: Pharmaceutical Technology